BNP Paribas Financial Markets Has $673,000 Stake in Celcuity Inc. (NASDAQ:CELC)

BNP Paribas Financial Markets lifted its position in shares of Celcuity Inc. (NASDAQ:CELC) by 2,083.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,110 shares of the company’s stock after buying an additional 43,044 shares during the period. BNP Paribas Financial Markets owned about 0.12% of Celcuity worth $673,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Samlyn Capital LLC raised its position in shares of Celcuity by 92.4% in the second quarter. Samlyn Capital LLC now owns 1,326,953 shares of the company’s stock valued at $21,735,000 after purchasing an additional 637,190 shares during the period. Driehaus Capital Management LLC raised its holdings in Celcuity by 62.3% in the 2nd quarter. Driehaus Capital Management LLC now owns 204,592 shares of the company’s stock valued at $3,351,000 after acquiring an additional 78,525 shares during the period. Blue Owl Capital Holdings LP bought a new position in Celcuity in the 2nd quarter valued at about $1,065,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Celcuity during the second quarter worth approximately $888,000. Finally, Point72 Asset Management L.P. bought a new stake in shares of Celcuity during the second quarter worth approximately $951,000. 63.33% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CELC. Lifesci Capital initiated coverage on shares of Celcuity in a research report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target for the company. Stifel Nicolaus lifted their price objective on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Celcuity in a research report on Friday, November 15th. Finally, Needham & Company LLC restated a “buy” rating and issued a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Celcuity presently has an average rating of “Buy” and a consensus price target of $29.17.

Celcuity Price Performance

NASDAQ:CELC opened at $12.61 on Friday. Celcuity Inc. has a 52-week low of $11.51 and a 52-week high of $22.19. The stock has a fifty day moving average of $14.39 and a 200 day moving average of $15.50. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The firm has a market capitalization of $468.21 million, a price-to-earnings ratio of -4.83 and a beta of 0.74.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.